胆碱酯酶抑制剂与阿尔茨海默病患者肾功能下降的关联
中位随访3.0年,ChEI使用与CKD进展风险降低18%(调整HR 0.82;95%CI 0.71-0.96)及死亡风险降低21%(0.79;0.72-0.86)相关。
要点
- 在新诊断AD患者中,启用ChEI与CKD进展风险降低18%相关(调整HR 0.82;95%CI 0.71-0.96)。
- ChEI使用与死亡风险降低21%相关(调整HR 0.79;95%CI 0.72-0.86)。
- 结果在亚组、ChEI亚类及竞争风险分析中一致。
核心结论
- 在常规诊疗的AD患者中,使用ChEI(对比未使用)与较低的CKD进展风险相关。
研究设计与样本
- 研究比较新诊断AD后90天内启用或未启用ChEI的患者,利用常规血清肌酐检测评估eGFR变化。
- 中位随访3.0年,采用逆概率治疗加权Cox回归估计风险比。
主要发现
- CKD进展复合结局(eGFR下降超过30%、启动透析/移植或CKD归因死亡)共1231例事件,ChEI使用与CKD进展风险降低18%相关(调整HR 0.82;95%CI 0.71-0.96)。
- 次要结局死亡风险降低21%(调整HR 0.79;95%CI 0.72-0.86)。
- 结果在亚组、ChEI亚类及考虑竞争风险后一致。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical evidence shows that activation of the cholinergic anti-inflammatory pathway (CAP) may have direct and indirect beneficial effects on the kidney. Cholinesterase inhibitors (ChEIs) are specific Alzheimer's dementia (AD) therapies that block the action of cholinesterases and activate CAP. Here, we explored a plausible effect of ChEIs on slowing kidney function decline by comparing the risk of CKD progression among patients with newly diagnosed AD that initiated ChEI or not within 90 days. Using complete information of routine serum creatinine tests, we evaluated changes in estimated glomerular filtration rate (eGFR) and defined the outcome of chronic kidney disease (CKD) progression as the composite of an eGFR decline of over 30%, initiation of dialysis/transplant or death attributed to CKD. A secondary outcome was death. Inverse probability of treatment-weighted Cox regression was used to estimate hazard ratios. Among 11, 898 patients, 6,803 started on ChEIs and 5,095 did not. Mean age was 80 years (64% women) and the mean eGFR was 68 ml/min/1.73m2. During a median 3.0 years of follow-up, and compared to non-use, ChEI use was associated with 18% lower risk of CKD progression (1,231 events, adjusted hazard ratio 0.82; 95% confidence interval 0.71-0.96) and a 21% lower risk of death (0.79; 0.72-0.86). Results were consistent across subgroups, ChEI subclasses and after accounting for competing risks. Thus, in patients with AD undergoing routine care, use of ChEI (vs no-use) was associated with lower risk of CKD progression.
引用
- Xu H, Garcia-Ptacek S, Bruchfeld A, et al. Association between cholinesterase inhibitors and kidney function decline in patients with Alzheimer's dementia. Kidney Int. 2022. PMID: 36341731. doi:10.1016/j.kint.2022.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。